INDICATION AND USAGE
DALVANCE® (dalbavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin
structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus
aureus (including methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae,
Streptococcus dysgalactiae, Streptococcus anginosus group (including S. anginosus, S. intermedius, S. constellatus) and
Enterococcus faecalis (vancomycin-susceptible strains).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial
agents, DALVANCE should be used only to treat infections that are proven or strongly suspected to be caused by susceptible
IMPORTANT SAFETY INFORMATION
DALVANCE is contraindicated in patients with known hypersensitivity to dalbavancin.
Warnings and Precautions
Serious hypersensitivity (anaphylactic) and skin reactions have been reported with glycopeptide antibacterial agents, including
DALVANCE. Exercise caution in patients with known hypersensitivity to glycopeptides due to the possibility of cross-sensitivity.
If an allergic reaction occurs, treatment with DALVANCE should be discontinued.
Rapid intravenous infusion of DALVANCE can cause reactions, including flushing of the upper body, urticaria, pruritus, rash,
and/or back pain.
ALT elevations with DALVANCE treatment were reported in clinical trials.
Clostridium difficile-associated Diarrhea
Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including
DALVANCE, with severity ranging from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.
Development of Drug-resistant Bacteria
Prescribing DALVANCE in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the
patient and increases the risk of the development of drug-resistant bacteria.
The most common adverse reactions in patients treated with DALVANCE were nausea (4.7%), headache (3.8%), and diarrhea
Use in Specific Populations
There have been no adequate and well-controlled studies with DALVANCE in pregnant or nursing women.
DALVANCE should only be used if the potential benefit justifies the potential risk in these populations.
In patients with renal impairment whose known creatinine clearance is less than 30 mL/min and who are not receiving
regularly scheduled hemodialysis, the recommended regimen of DALVANCE is 1125 mg, administered as a single
dose, or 750 mg followed one week later by 375 mg. No dosage adjustment is recommended for patients receiving
regularly scheduled hemodialysis, and DALVANCE can be administered without regard to the timing of hemodialysis.
Caution should be exercised when prescribing DALVANCE to patients with moderate or severe hepatic impairment
(Child-Pugh Class B or C) as no data are available to determine the appropriate dosing in these patients.
Please see Full